Format

Send to

Choose Destination
Maturitas. 2019 Feb;120:47-52. doi: 10.1016/j.maturitas.2018.11.014. Epub 2018 Nov 23.

Antihistamine use and risk of ovarian cancer: A population-based case-control study.

Author information

1
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. Electronic address: freija@cancer.dk.
2
Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
3
Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark.
4
Cell Death & Metabolism, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark.
5
Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
6
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Abstract

OBJECTIVE:

Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study.

STUDY DESIGN:

Cases (n = 5 556) comprised all women in Denmark aged 30-84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries.

MAIN OUTCOME MEASURES:

We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer.

RESULTS:

Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90-1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93-1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes.

CONCLUSION:

Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

KEYWORDS:

Antihistamines; Cancer prevention; Case-control study; Menopause; Ovarian neoplasms; Pharmacoepidemiology

PMID:
30583764
DOI:
10.1016/j.maturitas.2018.11.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center